252 related articles for article (PubMed ID: 12688334)
1. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease.
Pérez Sánchez I; Pérez Corrala A; Menarguez Palanca J; Mayayo Crespo M; Escudero Soto A; Pintado Cros T
Leuk Lymphoma; 2003 Mar; 44(3):557-9. PubMed ID: 12688334
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome.
Gupta R; Abdalla SH; Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):615-9. PubMed ID: 10492088
[TBL] [Abstract][Full Text] [Related]
3. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults.
Shaw GR
Br J Haematol; 2005 Oct; 131(2):180-4. PubMed ID: 16197447
[TBL] [Abstract][Full Text] [Related]
4. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
5. [Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies].
Gérard J; Dubois-Galopin F; Gardembas-Pain M; Defaux JB; Schmidt-Tanguy A; Godon A; Geneviève F; Blanchet O; Ifrah N; Zandecki M
Ann Biol Clin (Paris); 2005; 63(6):653-9. PubMed ID: 16330386
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
[TBL] [Abstract][Full Text] [Related]
7. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases.
Mimiola E; Bomben R; De Matteis G; Perbellini O; Guglielmelli P; Bonifacio M; Parisi A; Gattei V; Zamò A; Mannelli F; García Montero AC; Zanotti R
Hematol Oncol; 2019 Dec; 37(5):628-633. PubMed ID: 31523839
[TBL] [Abstract][Full Text] [Related]
10. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
[TBL] [Abstract][Full Text] [Related]
11. Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).
Mohamed M
Blood; 2014 Jan; 123(3):314. PubMed ID: 24575445
[No Abstract] [Full Text] [Related]
12. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
13. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.
Cabello AI; Collado R; Ruiz MA; Martínez J; Navarro I; Ferrer R; Sosa AM; Carbonell F
Leuk Res; 2005 Apr; 29(4):365-70. PubMed ID: 15725469
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
16. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable.
Gattermann N; Billiet J; Kronenwett R; Zipperer E; Germing U; Nollet F; Criel A; Selleslag D
Blood; 2007 Feb; 109(3):1334-5. PubMed ID: 17244688
[No Abstract] [Full Text] [Related]
17. The role of JAK2 mutations in RARS and other MDS.
Hellström-Lindberg E; Cazzola M
Hematology Am Soc Hematol Educ Program; 2008; ():52-9. PubMed ID: 19074058
[TBL] [Abstract][Full Text] [Related]
18. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
19. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
[No Abstract] [Full Text] [Related]
20. Chronic lymphocytic leukemia associated with myelodysplastic syndrome with ring sideroblasts.
Charafeddine KM; Ibrahim GY; Mahfouz RA; Zaatari GS; Salem ZM
South Med J; 2010 Aug; 103(8):823-7. PubMed ID: 20622728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]